ArticleScientific reports2025
Druggable genome-wide Mendelian randomization integrating GWAS and eQTL/pQTL data identifies targets for lung squamous cell carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- SHAP-interpretable machine learning integrating exposures and multi-omics reveals immune alterations and biomarkers in COPD-lung cancer comorbidity.Frontiers in immunology · 2026Article
- CLEC4G Promotes Pancreatic Cancer Progression by Suppressing Cathepsin B-Mediated Ferroptosis: Evidence From Mendelian Randomization Study and Experimental Validation.Human mutation · 2026Article
- Potential ofFrontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Lung squamous cell carcinoma (LUSC) is one of the most common types of non-small cell lung cancer with poor prognosis. Druggable genome-wide Mendelian randomization (MR) was conducted to discover LUSC-related targets using expression quantitative trait loci (eQTL) and protein QTL (pQTL) in the ieu_b_4953 dataset and finngen dataset. Bayesian co-localization analysis, summary‑data‑based MR (SMR) analysis, and HEIDI test were conducted to verify the causal associations between genes and LUSC risk. Prediction of prognosis and immune infiltration was performed at the transcriptomic level, and expression patterns of genes were analyzed at the single-cell level. We identified DNMT1, ACSS2, YBX1, SELENOS, PPARA, MST1, CPA4, and MPO as LUSC-related genes based on MR analysis. Although Bayesian co-localization analysis showed negative co-localization results (PPH3 + PPH4 < 0.8), positive SMR (p < 0.05) and HEIDI (p > 0.05) were found in the ieu_b_4953 dataset and finngen dataset. Blood CPA4 and DNMT1 might be protective factors for bladder cancer and allergic rhinitis, respectively. Patients with low expression of CPA4, DNMT1 and YBX1 had better prognosis, while patients with high expression of MST1 had better prognosis. Tumor samples exhibited reduced infiltration of CD4 cells, CD8 cells, activated dendritic cells, eosinophils, myeloid-derived suppressor cells (MDSCs), macrophages, and mast cells. At the single-cell level, DNMT1, SELENOS and YBX1 were highly expressed in endothelial cells, epithelial cells, fibroblasts, hepatocytes, mast cells, and monocytes/macrophages. MST1 was overexpressed in hepatocytes. This study might deepen the understanding of the LUSC pathogenesis and identify potential targets for the management of LUSC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.